Sartorius AGSARTF -1.83%85 FCF Margin % is 12.37% as of Mar. 2026, which is 46% above its 10-year median of 8.48. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sartorius AG ranks better than 79.02% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sartorius AG's Free Cash Flow for the
three
months ended in Mar. 2026 was $129 Mil. Sartorius AG's Revenue for the
three
months ended in Mar. 2026 was $1,039 Mil. Therefore, Sartorius AG's FCF Margin % for the quarter that ended in Mar. 2026 was 12.37%.
The historical rank and industry rank for Sartorius AG's FCF Margin % or its related term are showing as below:
SARTF'
s FCF Margin % Range Over the Past 10 Years
Min: 0.67 Med: 8.48 Max: 16.75
Current: 12.49
During the past 13 years, the highest FCF Margin % of Sartorius AG was 16.75%. The lowest was 0.67%. And the median was 8.48%.
SARTF's FCF Margin % is ranked better than 79.02% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs SARTF: 12.49
Sartorius AG FCF Margin % Related Terms
Sartorius AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sartorius AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a FCF Margin % of 12.37% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sartorius AG and its competitors. This is 46% above median its historical median of 8.48. Over the past decade, Sartorius AG's FCF Margin % has ranged from 0.67 to 16.75. According to the industry distribution chart, Sartorius AG ranks #171 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Sartorius AG's FCF Margin % too high?
Sartorius AG's current FCF Margin % of 12.37% is 46% above median its 10-year median of 8.48. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 16.75. Based on the distribution chart, Sartorius AG ranks #171 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #171 out of 815 companies for FCF Margin %. This places Sartorius AG in the top 21% of its industry — outperforming the majority of peers. Historically, Sartorius AG's own FCF Margin % has ranged from 0.67 to 16.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sartorius AG and its competitors. Sartorius AG's current FCF Margin % is 12.37%, which is 46% above median its own 10-year median of 8.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current FCF Margin % is 12.37%, which is 46% above median its 10-year median of 8.48. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sartorius AG (SARTF), the current FCF Margin % is 12.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
FCF Margin %: 12.37% (46% above median its 10-year median of 8.48)
GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
